As of Jul 21
| +0.04 / +0.86%|
The 6 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 7.50, with a high estimate of 9.50 and a low estimate of 3.50. The median estimate represents a +59.57% increase from the last price of 4.70.
The current consensus among 6 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.